Axs Vecta 71
Payments companies reported to CMS as associated with Axs Vecta 71. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Axs Vecta 71, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Axs Vecta 71
These are the largest totals companies reported as associated with Axs Vecta 71. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jan-Karl Burkhardt | New York, NY | Neurological Surgery | $24,762.63 |
| Ansaar Rai | Morgantown, WV | Neuroradiology | $20,188.75 |
| Italo Linfante | Miami, FL | Neuroradiology | $19,428.86 |
| Ben Waldau | Sacramento, CA | Neurological Surgery | $18,185.90 |
| Omar Choudhri | Philadelphia, PA | Neurological Surgery | $17,000.00 |
| Santiago Ortega Gutierrez | Iowa City, IA | Vascular & Interventional Radiology | $12,687.94 |
| Sohyun Boo | Morgantown, WV | Neuroradiology | $12,163.70 |
| Donald Frei | Englewood, CO | Diagnostic Radiology | $11,699.61 |
| Michael Stiefel | Atlanta, GA | Neurological Surgery | $10,859.82 |
| David Fiorella | Stony Brook, NY | Neuroradiology | $10,575.00 |
Prescribed Axs Vecta 71?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.